Zentalis Pharmaceuticals Inc. (ZNTL): Price and Financial Metrics
GET POWR RATINGS... FREE!
ZNTL Stock Price Chart Interactive Chart >
ZNTL Price/Volume Stats
| Current price | $24.75 | 52-week high | $87.19 |
| Prev. close | $22.33 | 52-week low | $17.33 |
| Day low | $21.92 | Volume | 933,400 |
| Day high | $25.32 | Avg. volume | 619,457 |
| 50-day MA | $31.36 | Dividend yield | N/A |
| 200-day MA | $57.80 | Market Cap | 1.15B |
Zentalis Pharmaceuticals Inc. (ZNTL) Company Bio
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer. The company was founded by Kevin D. Bunker on December 23, 2014 and is headquartered in New York, NY.
Latest ZNTL News From Around the Web
Below are the latest news stories about Zentalis Pharmaceuticals Inc that investors may wish to consider to help them evaluate ZNTL as an investment opportunity.
Zentalis Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational UpdateFast Track designation granted by the U.S. Food and Drug Administration (FDA) to Wee1 Inhibitor, ZN-c3, for the treatment of uterine serous carcinoma (USC) Initiated two additional trials with ZN-c3, including a potentially registrational biomarker-driven Phase 2 trial and a Phase 1/2 trial in combination with GSK’s PARP inhibitor, niraparib, in ovarian cancer Announced the addition of a preclinical BCL-xL heterobifunctional degrader candidate to its pipeline Ended year with $339.9 million in ca |
Zentalis Pharmaceuticals to Participate in Two Upcoming Investor ConferencesNEW YORK and SAN DIEGO, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Anthony Sun, MD, Chairman and Chief Executive Officer of Zentalis, will participate in fireside chats at two upcoming virtual investor conferences. Presentation Details: Event: Guggenheim Oncology ConferenceDate |
Leerink Partners Maintains a Buy Rating on Zentalis Pharmaceuticals (ZNTL)Leerink Partners analyst Andrew Berens maintained a Buy rating on Zentalis Pharmaceuticals (ZNTL – Research Report) yesterday. The company's shares closed last Wednesday at $72.81. According to TipRanks.com, Berens has 0 stars on 0-5 stars ranking scale with an average return of -3.8% and a 44.1% success rate. Berens covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Turning Point Therapeutics, and Global Blood Therapeutics. Zentalis Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $104.33. See the top stocks recommended by analysts >> The company has a one-year high of $87.19 and a one-year low of $34.48. |
Zentalis Pharmaceuticals Inc (ZNTL) COO Kevin D. Bunker Sold $792,400 of SharesCOO of Zentalis Pharmaceuticals Inc (30-Year Financial, Insider Trades) Kevin D. Bunker (insider trades) sold 10,000 shares of ZNTL on 12/20/2021 at an average price of $79.24 a share. |
We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash WiselyThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining... |
ZNTL Price Returns
| 1-mo | -4.22% |
| 3-mo | -51.77% |
| 6-mo | -68.11% |
| 1-year | -55.68% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -70.56% |
| 2021 | 61.84% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...